Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan says US FDA's generic user fee not discriminatory despite foreign inspection cost differential

This article was originally published in SRA

Executive Summary

US generic manufacturer Mylan believes that any claims of bias against foreign manufacturers within the US Food and Drug Administration's proposed generic drug user fee plan are "misplaced" and that the programme offers parity for all industry participants1. The US firm, seen as a "driving force" behind the proposal, also sees the programme securing American competitiveness and jobs.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS116618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel